



Case 4-32185P1

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 335542800 US

Express Mail Label Number

January 22, 2004

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

PAIVI JAANA KUKKOLA

APPLICATION NO: 09/966,960

FILED: SEPTEMBER 28, 2001

FOR: THYROMIMETIC ORGANIC COMPOUNDS

Art Unit: 1624

Examiner: Truong, T. N.

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER TRANSMITTAL / FEE LETTER


Sir:

Enclosed herewith is a Terminal Disclaimer in the above-identified application.

The Commissioner is hereby authorized to charge the \$110 fee under 37 CFR §1.20(d) and any additional fees that may be required to Deposit Account No. 19-0134 in the name of Novartis. An additional copy of this paper is here enclosed.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080

  
Norbert Gruenfeld  
Agent for Applicant  
Reg. No. 30,061  
(862) 778-7853

Date: January 22, 2004



Case 4-32185P1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

PAIVI JAANA KUKKOLA

APPLICATION NO: 09/966,960

FILED: SEPTEMBER 28, 2001

FOR: THYROMIMETIC ORGANIC COMPOUNDS

Art Unit: 1624

Examiner: Truong, T. N.

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Sir:

Novartis AG having a place of business at Basel, Switzerland, represents that it is the assignee and owner of the entire interest in the above-identified application by virtue of an assignment which is being transmitted for recordation in the United States Patent and Trademark Office concurrently herewith. A copy is attached hereto.

Novartis AG hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term defined in 35 USC §154-156 and §173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending **Application No. 09/931,683** filed August 16, 2001. Said Application No. 09/931,683 is also assigned to Novartis AG by virtue of an assignment recorded in the United States Patent and Trademark Office on July 30, 2001 (Reel/Frame 012032/0914).

Novartis AG hereby agrees that any patent granted on the above-identified application shall be enforceable only for and during such period that it and any patent granted on Application No. 09/931,683 are commonly owned. This agreement runs with any patent granted on the above-identified application and is binding upon the grantee, its successors or assigns.


In making the above disclaimer, Novartis AG does not disclaim the terminal part of any patent granted on the above-identified application that would extend to the expiration date of the full statutory term as defined in 35 USC §154-156 and §173 of any patent granted on Application No. 09/931,683, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held

unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

A terminal disclaimer fee under 37 CFR §1.20(d) is included.

Signed this 22<sup>nd</sup> day of January, 2004 by the undersigned agent of record.

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080

  
\_\_\_\_\_  
Norbert Gruenfeld  
Agent for Applicant  
Reg. No. 30,061  
(862) 778-7853

Encl.: Copy of Request for Recordation of Assignment

## PATENTS ONLY

Case No. 4-32185P1

(Previously Case No. 4-30879E/N1/CGG2114)

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

## 1. Name of conveying party(ies):

Paivi Jaana Kukkola

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

## 3. Nature of conveyance:

☒ Assignment☐ Merger☐ Security Agreement☐ Change of Name☐ Other \_\_\_\_\_

Execution Date: September 28, 2001

## 2. Name and address of receiving party(ies)

Name: Novartis AG

Street Address: Lichtstrasse 35

City: Basel State: Switzerland ZIP: 4056

Additional name(s) & address(es) attached? ☐ Yes ☒ No

## 4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: \_\_\_\_\_

## A. Patent Application No.(s)

09/966,960

## B. Patent No.(s)

Additional numbers attached? ☐ Yes ☒ No

## 5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Thomas Hoxie

Internal Address: Novartis

Corporate Intellectual Property

Street Address: One Health Plaza, Building 430

City: East Hanover State: NJ ZIP: 07936-1080

## 6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 3.41) \$ 40

☐ Enclosed☒ Authorized to be charged to deposit account and any other additional fees required.

## 8. Deposit account number:

19-0134 (in the name of Novartis)

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

## 9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Norbert Gruenfeld

Name of Person Signing  
Reg. No. 30,061

Norbert Gruenfeld

Signature

January 22, 2004

Date

☒ Certificate of Express Mail below

Total number of pages including cover sheet, attachments, and document: 2

Mail documents to be recorded with required cover sheet information to:

Direct to the US Patent and Trademark Office, PO Box 1450  
Alexandria, VA 22313-1450FILING BY 'EXPRESS MAIL'  
UNDER 37 CFR 1.10

EV 336722286 US

Express Mail Label Number

January 22, 2004

Date of Deposit

ASSIGNMENT

I,

Paivi Jaana Kukkola                      residing at              6 Bouwrey Place  
Whitehouse Station, New Jersey 08889,

for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell and assign to **Novartis AG**, a company organized under the laws of the Swiss Confederation, having a place of business at Schwarzwaldallee 215, Basel, Switzerland 4058, its successors, assigns and legal representatives, all my right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to me by local laws or by treaty, including any international convention for the protection of industrial property, in and for the United States and its territories and possessions in and to the invention entitled:

THYROMIMETIC ORGANIC COMPOUNDS

invented by me and described in the application for United States Letters Patent executed on even date herewith including (1) said application for United States Letters Patent and all continuations and divisions thereof (including further continuations and divisions such as, but not limited to, continuations of continuations and divisions of continuations), (2) all United States Letters Patent which may be issued and/or granted on all such applications, (3) all applications for reissues and extensions of and reexamination certificates for all such United States Letters Patent and (4) all reissues and extensions and reexamination certificates issued for all such United States Letters Patent, the said interest being the entire ownership of said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates to be held and enjoyed by the said Novartis AG and its successors and assigns to the full end of the terms to which said United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates may be granted and/or issued, as fully and entirely as the same would have been held and enjoyed by me if this sale, assignment and transfer had not been made;

And I hereby agree to sign and/or execute any further documents and/or instruments which may be necessary, lawful and proper in and/or for the filing and/or prosecution of said applications for United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates and/or the granting and/or issuance thereof and/or to otherwise secure title to said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates in said assignee.

Signed this 28<sup>th</sup> day of September, 2001

by

  
Paivi Jaana Kukkola